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ABSTRACT 
_____________________________________________________________________ 
 
Background: 
India is the diabetic capital of the world with 8.7% of the population having diabetes 
mellitus.(1). India also has a high burden of Tuberculosis (TB) and this amounts to 
significant mortality and morbidity. Diabetes mellitus (DM) has a negative impact on 
innate and adaptive immune responses which may impact treatment outcomes in patients 
with TB like cure rates, relapse rates and mortality.  In this study we aim to study the 
clinical characteristics of diabetic and non-diabetic patients  diagnosed with tuberculosis 
their sputum smear conversion rates and the treatment outcomes. We also wish to look at 
the relationship between glycaemic control and treatment outcomes of TB.  
 
Methodology: 
In this prospective observational cohort study, 125 patients with sputum positive 
Tuberculosis were recruited. Among these, 68 patients (55 %) had diabetes mellitus and 
56 patients (45%) were non-diabetics. They were followed up for a total duration of 6 
months. Baseline anthropometric data was documented along with sputum AFB smear, 
AFB culture, Gene Xpert, glycosylated Haemoglobin and blood glucose levels. They 
were followed up at 2 months when sputum AFB smears and blood glucose levels were 
repeated.  Those with sputum AFB smear positivity were followed up monthly till 
negative sputum smears were documented. At 6 months sputum AFB smear, AFB 
culture, Gene Xpert, glycosylated Haemoglobin and blood glucose levels were repeated. 
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Treatment outcomes in terms of time to conversion of Sputum smears, mortality and cure 
rates were compared between the two groups.  
Results: We recruited 124 patients of which 68 were diabetic and 56 did not have 
diabetes. 11 patients (9%) of the patients were sputum positive at 2 months, among 
whom 6 were diabetics and 5 were non-diabetics (NDM). We demonstrated that 
smoking, Chronic Obstructive Pulmonary Disease, high bacillary load and the presence 
of fibrocavitatory lesions were associated delayed sputum conversion. We could not 
demonstrate an association between delayed sputum conversion and diabetes with poor 
glycaemic control. We also demonstrated a significant reduction in HbA1c after 6 
months of Anti tuberculous therapy in the diabetic group [Mean difference – 1.76, 
00195% CI of difference – (1.01 – 2.52) p value – 0.001]. There was no treatment failure 
recorded in our study. 57 % in the DM group and 50 % in the NDM group were either 
cured or had completed treatment successfully. The mortality rates were 15 % and 7% in 
the DM and NDM groups respectively. There was a significant association between the 
presence of CKD and mortality in the study population Patients with fatal outcomes had 
a lower albumin level [ F-0.425, p value – 0.01, mean difference -0.53, 95 % CI of 
difference (-0.945 to – 0.106)] and higher creatinine levels [ F-71.9, p value – 0.001, 
mean difference 1.29, 95 % CI of difference (0.84 to 1.74)].  
Conclusions: In this study, we demonstrated that Diabetes was not associated with poor 
outcomes in patients with pulmonary TB. There was also no association between DM 
and delayed sputum conversion. We also could not demonstrate any association between 
poor glycaemic control and delayed sputum conversion or mortality.  
Keywords: Pulmonary Tuberculosis, Diabetes Mellitus, Outcomes  
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INTRODUCTION 
_____________________________________________________________________ 
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium 
tuberculosis. While it typically affects the lungs, it can affect virtually any part of the 
body. TB spreads from person to person by droplet method of transmission. (2) 
TB is the leading cause of death due to an infective disease in the world(3). Active TB 
develops in  hosts with impaired immunity and in people with increased exposure to 
patients with active tuberculosis. 
Diabetes Mellitus (DM) is a chronic, non-communicable disease. Diabetes occurs when 
the body either cannot produce enough of the hormone insulin, or it is not able to use 
insulin effectively. Type 2 diabetes, is a condition where the body does not use insulin 
properly, resulting in elevated levels of glucose in the bloodstream. Diabetes mellitus has 
been shown to confer a threefold increased risk of developing TB.  
The prevalence of diabetes is increasing, especially in the Asian countries, where the 
prevalence of TB is also on an upward trend. Globally, 70% of those with DM are in TB 
endemic regions. Diabetes mellitus has a negative impact on innate and adaptive immune 
responses which may impact treatment outcomes in patients with TB like cure rates, 
relapse rates and mortality. (7–12)  This interplay between DM and TB is a complex one 
and if unchecked, could have disastrous consequences. In this study we aim to study the 
clinical characteristics of diabetic and non-diabetic patients  diagnosed with tuberculosis 
their sputum smear conversion rates, treatment outcomes and the factors that affect them. 
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AIMS AND OBJECTIVES 
_____________________________________________________________________ 
Aim: 
To study the outcomes of pulmonary tuberculosis among patients with diabetes mellitus. 
 
Primary Objectives: 
1. To study the cure rates of diabetic patients with pulmonary Tuberculosis 
2. To assess sputum conversion rates among diabetic patients with pulmonary       
Tuberculosis and the time to clinical recovery 
3. To identify the determinants of treatment outcomes of pulmonary Tuberculosis 
 
Secondary Objectives:  
1. To assess the effects of glycaemic control on treatment outcomes of sputum             
positive pulmonary tuberculosis 
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REVIEW OF LITERATURE 
 
Introduction 
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium 
tuberculosis (M.tb). While it typically affects the lungs, it can affect virtually any part of 
the body. TB spreads from person to person by droplet method of transmission. (2) 
Active TB develops in  hosts with impaired immunity secondary to diseases like 
Diabetes Mellitus (DM), Human Immunodeficiency Virus (HIV) infection, patients on 
immunosuppressants etc; and in people with increased exposure to patients with active 
tuberculosis. 
 Diabetes Mellitus (DM) is a chronic, non-communicable disease. Diabetes occurs when 
the body either cannot produce enough of the hormone insulin, or it is not able to use 
insulin effectively. Type 2 diabetes, is a condition where the body does not use insulin 
properly, resulting in elevated levels of glucose in the bloodstream. It is associated with a 
number of microvascular and macrovascular complications and is associated with an 
increased susceptibility to infections like tuberculosis(4). The prevalence of diabetes is 
increasing, especially in the Asian countries, where the prevalence of TB is also on an 
upward trend. The interplay between DM and TB is a complex one and if unchecked, 
could have disastrous consequences.  
Globally, 70% of those with DM are in TB endemic regions. In countries with the 
highest burden of TB, the prevalence of DM ranges from 2% to 9% (5). Also eight of the 
ten countries with the highest incidence of DM have been classified as high burden 
countries for TB by the World Health Organization (WHO) (6) 
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Burden of pulmonary tuberculosis 
Globally in 2015, there were an estimated 10.4 million incident cases of TB equivalent to 
142 cases per 100,000 population. According to the WHO in 2015, there were 2.2 million 
cases of TB in India out of a global incidence of 9.6 million.  According to the WHO, 
around one-third of those developing active TB disease remain undiagnosed or are not 
notified to the public health authorities. This proportion of patients could account to close 
to 3.6 million individuals.  
 The estimated TB prevalence figure for 2015 is given as 2.5 million. Around 40 % of the 
Indian population is estimated to be infected with TB bacteria and the vast majority have 
latent rather than active TB. (13) 
According to the TB India 2016 Revised National TB Control Programme Annual Status 
Report, New Delhi, 902,732 people were diagnosed to have sputum positive tuberculosis. 
The cure rate for new sputum positive cases in 2014 was 83%. In Tamilnadu, 54,547 new 
sputum positive cases were diagnosed. The cure rate for sputum positive cases in 2014 
was 80% in Tamilnadu. 9,132,306 cases were tested for AFB in sputum of which 
902,732 were positive.(14) The prevalence of TB among DM patients ranges from 0.38% 
to 14% with the overall median global prevalence being 4.1% (15).   
Burden of diabetes mellitus  
According to the international Diabetes federation, 415 million people have diabetes. The 
global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 
1980 to 8.5% in 2014. Diabetes prevalence has been rising more rapidly in middle- and 
low-income countries. Around 80% of patients with DM live in low income and 
developing countries(16). The prevalence of DM in south east Asia is 8.4% (17).  India is 
the diabetic capital of the world with 69.2 million people living with diabetes amounting 
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to a prevalence of 8.7% as per national surveillance data from 2015 (1). The prevalence 
of DM among TB patients ranges from 1.9% to 45%, with the median global prevalence 
being 16%(15) . The prevalence of DM among TB patients was found to be 15.2 % in a 
study from south India (18).  Systematic screening for tuberculosis in people with 
diabetes could improve early detection in settings with a high tuberculosis burden. The 
number needed to be screened to detect one previously undetected case of tuberculosis in 
countries with a high tuberculosis burden range from 17 to 776 (19–21). 
Natural history of tuberculosis infection 
M. tb is manly a pathogen of the respiratory system, but it also can disseminate to the 
other organs and can cause extrapulmonary TB.  This pathogen has airborne transmission 
and once a host is exposed to M. tb it may be eliminated or may persist in the host. 
Elimination of the bacilli may be by an innate immune response or by an adaptive 
immune response based on memory T cell response. If not eliminated it persists as a 
latent TB infection which may progress to develop a subclinical infection and later active 
TB. Progression from latent TB to active TB may be subtle and those with subclinical TB 
can also transmit M. tb.(22) A person once infected with TB, can infect 3-10 people per 
year but only a few of them develop active TB. (23) People with active TB, have an 
average duration of infectiousness of more than one year. Among those infected with M. 
tb, 5-15% will develop active TB over period of months or few years. The remainder 
carry a risk of developing active TB throughout their lifetime.(24) In the absence of 
treatment, 50 % of those developing active TB succumb to the illness(25).  
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Figure 1. Spectrum of Tuberculosis. 
Adapted from Pai M, et al. Tuberculosis. Nat Rev Dis Primer. 2016 Oct 27;2:16076. 
Immunology of tuberculosis 
M. tb enters the human body through the respiratory tract. After inhalation, it is 
translocated to the lower respiratory tract where it is phagocytosed by alveolar 
macrophages. The bacilli then blocks fusion of the phagosome with the lysosome. Then 
the bacilli through its specialised secretion system - ESX-1 secretion system, which is 
encoded by Region of difference – 1 (RD1) region in its genome; disrupts the 
phagosomal membrane thereby leading to the release of mycobacterial DNA and other 
products into the cytoplasm of the macrophage. This ESX-1 secretion system contributes 
significantly to the virulence of M.tb.(22,26).  
If the macrophages fail to eliminate the bacilli, it then gains access to the pulmonary 
interstitium either through the infected macrophages that migrate to the lung parenchyma 
or by direct infection of the alveolar epithelial cells. Once in the parenchyma, a multi 
cellular host response is mounted and a granuloma is formed. M. tb is then transported to 
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the lymph nodes for T – cell priming by the dendritic cells or the inflammatory 
monocytes.(27) Additionally, M.tb can delay the initial priming of T-cells and the 
trafficking of T-cells into the lungs. Granuloma formation is a multicellular host response 
to wall of the TB bacilli, preventing spread to different tissues in the body. However M. 
tb can replicate within these cells and if the granuloma is unable to contain these bacilli, 
it can disseminate to other tissues.(22) 
 
Figure 2. Mycobacterium tuberculosis infection 
Adapted from Pai M, et al. Tuberculosis. Nat Rev Dis Primer. 2016 Oct 27;2:16076. 
Pathogenesis of tuberculosis in diabetes mellitus 
Diabetes increases the risk of active tuberculosis by about three times, principally by 
impairing the host-defences and thereby increasing the risk of progression from 
tuberculosis infection to active disease. (16,23–27).  
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A few animal studies have tried to elucidate the pathogenesis of increased susceptibility 
to TB in DM. Mice that have been infected with M. Tb have demonstrated higher 
bacterial loads of M. Tb compared to euglycemic mice, regardless of the route of 
inoculation of this pathogen. Diabetic mice have been shown to have significantly lower 
production of interferon gamma, interleukin -12 which are proinflammatory cytokines, 
playing a major role in the immune response to TB. Also fewer M. tuberculosis antigen 
(ESAT6) responsive T cells were demonstrated in a study  in early M. tuberculosis 
infection suggestive of a diminished T helper 1 response(32,33). 
In experimental studies, insulin has been shown to have an immunomodulatory effect. It 
reduces the Th1 to Th2 cell number ratio, thereby decreasing the Th1 immunity and the 
IFN-γ to IL4 secretion ratio. These are regarded as anti-inflammatory effects. It also 
downregulates the production of proinflammatory cytokines and acute phase proteins and 
up regulates the production of anti-inflammatory cytokines(7). 
Diabetic patients without tuberculosis showed a strongly reduced non-specific IFN-γ 
production, which plays a role in inhibiting the initial growth of M.Tb. This reduced 
nonspecific immune response may be responsible for the increased risk of developing TB 
in patients with DM(8).  
Another study showed that IFN-gamma and IL-12 levels in TB patients with DM were 
significantly lower than in those TB patients without DM. Also, IL-10 production was 
lower in patient with TB and DM as compared to patients with TB without DM.  
Production of IFN- γ a proinflammatory cytokine, playing a major role in the immune 
response to TB, was significantly lower in diabetics with TB with poor glycaemic 
control, as compared to those with good glycaemic control. The levels of IFN-γ were 
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negatively correlated with levels of HbA1c. This could explain the delayed sputum 
culture conversion seen in diabetics with TB (9).  
 A study evaluating leucocyte function in patients with DM demonstrated that 
polymorphonuclear neutrophil cell chemotaxis was significantly lower as compared to 
normal non-diabetic controls. Intracellular bactericidal activity has also demonstrated to 
be impaired in Diabetics. Chemotaxis and intracellular bactericidal activity were further 
impaired in the setting of poor glycaemic control in these studies(10,11).  
All these studies  support the hypothesis that DM directly impairs the innate and adaptive 
immune responses necessary to counter the proliferation of TB bacilli.(7–12) 
Other factors that have been implicated in the increased susceptibility of diabetics to 
develop TB are alveolar macrophage dysfunction, pulmonary microangiopathy and 
micronutrient deficiencies. Studies have demonstrated the altered phagocytic function of 
alveolar macrophages in diabetics(34,35). 
Another mechanism of the effects of DM on TB can be explained by lower plasma levels 
of ATT drugs, as evidenced by the lower plasma concentrations of rifampicin among 
those with DM and TB(34,36,37). In one study, patients with TB and DM had a 53% 
lower mean exposure to rifampin as compared to TB patients without DM in the 
continuation phase of therapy. Also, the maximum plasma concentration of rifampicin 
achieved was lower in diabetics with TB as opposed to those with TB without DM.  A 
co-relation between plasma glucose concentration and exposure to Rifampicin was 
demonstrated in this study(38). Strangely, differences in the pharmacokinetics of 
rifampin, pyrazinamide, and ethambutol have not been detected in the intensive phase of 
ATT(39). Explanations suggested for this reduced exposure to rifampicin in the 
continuation phase of ATT among patients with TB and DM are the increase in body 
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weight from baseline in the continuation phase and possible differences in hepatic 
induction(39). A decrease in gastric acid secretion and impaired absorption of drugs also 
may contribute to this finding(37).  
Association between diabetes mellitus and tuberculosis 
Burden of disease 
The most potent risk factor for TB is Human Immunodeficiency 
Virus (HIV) infection. However, due to the high prevalence of DM in the world, its 
effect on TB burden has been shown to be greater than HIV infection in studies(31). TB 
affects DM in many aspects. Jean et.al, performed a systematic review of literature and 
identified 13 observational studies that looked at the association of TB with DM. A total 
of 17,698 cases of TB were identified among 1,786,212 participants. This study showed 
that compared with people who do not have diabetes, people with diabetes have a 3.11-
fold (95% CI 2.27–4.26) increased risk of developing active TB. This study also showed 
higher risks of developing TB in nations with a high background incidence of TB (12) 
The estimated global cases of incident tuberculosis attributable to diabetes have 
increased substantially in the 22 countries accounting for 80% of the global tuberculosis 
burden, from 10% in 2010 (40) to 15% in 2013. A 52% incident rise was also seen in the 
estimated diabetes prevalence in these countries, from 5·4% in 2010, to 8·2% in 2013 
(4).  A meta-analysis showed that DM patients in low- or middle-income countries were 
at a higher risk of developing TB as compared to those in high income countries(41). 
More than 40% of diabetes-associated tuberculosis cases are in India and China (42). 
Studies have shown that,  12%–13% of patients with tuberculosis had diabetes(43–46). 
DM was diagnosed at the time of diagnosis of TB in more than 60 % of patients in 2 
studies, showing that DM is under recognized (47,48).  Given the increased risk of 
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tuberculosis among diabetics, active screening based on symptoms is recommended by 
the WHO(49) 
 
A Mathematical modelling study on the incidence of DM and TB in India suggested that 
DM contributes to 15 % of the cases with pulmonary TB and 20 % of those with sputum 
positive pulmonary TB. It also showed that DM contributed to 80.5% and 86%  of  
annual incident cases of pulmonary tuberculosis and sputum positive pulmonary TB 
respectively, among the diabetic population (50).   
Epidemiology of  tuberculosis in diabetes mellitus 
TB is positively associated with reporting a diabetes diagnosis, longer duration of  daily 
smoking and greater household crowding with additional persons per room. TB was 
negatively associated with more education, a home with good floors and walls or with a 
good toilet, an urban  location and lesser number of people in the household (42). 
 Urbanization was found to increase the TB incidence in India because the annual risk of 
infection has been found to be 69% higher in urban than rural areas, which could be 
attributed to the increases in the prevalence of obesity and diabetes in urban areas, and 
increases in the prevalence of undernutrition in men who live in rural areas (51) 
Among those with tuberculosis, DM was more commonly seen in those aged older than 
35 years, patients with smear-positive pulmonary tuberculosis, current cigarette smokers, 
and those with recurrent tuberculosis (52–56). Among diabetics, tuberculosis was more 
commonly seen in those needing combined oral hypoglycaemic drugs and insulin, and 
those who had poorly controlled diabetes.(9,23,31). 
In retrospective study done in Chile, looking at 1529 patients with DM over a period of 
23 years, the 10-year risk of acquiring TB was 5.9 % among those with DM as compared 
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to the 0.8% among the general population. The 10 year risk of acquiring TB was 24.2 % 
among the patients with Diabetes on insulin as compared to 4.8 % among diabetics not 
requiring insulin (58).  
A study conducted in Tanzania also showed higher risk of acquiring TB among diabetics 
with low Body Mass Index (BMI), younger age group and insulin use(59).  A meta-
analysis showed that insulin use increased the risk of developing TB by 2.5 - fold (41). 
Studies have demonstrated that TB patients with DM usually have a higher body weight 
prior to commencement of therapy, which generally increases after treatment.  In a study 
from West Africa, obesity (Body Mass Index {BMI} > 30 kg ⁄ m2) was seen in 23% of 
diabetics with TB as compared to 3% in non-diabetics (60). Similarly in study conducted 
in Indonesia, 53% of TB patients with DM had a pre-treatment weight of more than 50 
Kg, while only 16.5% of non-diabetic patients had a weight more than 50 Kg (47). In 
contrast a study from South India showed that patients with DM and pulmonary TB had a 
lower BMI.  
A meta-analysis of 13 observational studies showed stronger associations between DM 
and TB in the those less than 40 years of age (12).  However other studies have shown 
that TB patients with DM are 10-20 years older than those without TB(31), which could 
be due to the older age of presentation of Type 2 DM which is the most prevalent form of 
DM.   
Patients with type 1 DM had a 3-5 fold risk of developing TB as compared to those with 
type 2 DM(59,61). Those with Type 1 DM were found to have more cavitatory lung 
lesions as compared to those without DM in a study(62) This was thought to be due to 
poor glucose control and longer duration of illness(63).  
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Clinical and laboratory characteristics of patients with diabetes mellitus and tuberculosis 
In a study done in Taiwan it was found that diabetic patients were significantly more 
likely to have any symptom, cough, haemoptysis, tiredness, weight loss, positive smear 
and higher smear positivity grades as compared with non-diabetics. With maximum 
symptoms and smear positivity grades in patients with HbA1C>9%.  (64) 
A meta-analysis showed that DM patients with a glycosylated haemoglobin level 
(HbA1c) ≥ 6.5%, a Fasting Blood Glucose level ≥ 120 mg/dl, were at 1.87–fold and 
3.30-fold increased risk of TB, respectively(41). A study conducted in South India 
showed that patients with DM and pulmonary TB had a greater likelihood of having a  
longer duration of DM and a poor glycaemic control(57). 
After exposure to viable M.Tb bacilli, hosts who do not clear all the bacilli can develop 
latent TB infection (LTB) where they are asymptomatic and do not transmit the 
bacilli(65). Those with LTB have a life-time risk of 5%–15% to further progress into 
active tuberculosis(66). Progression to active TB depends on the immune function of the 
host. A meta-analysis of observational studies on LTB among diabetics showed that DM 
patients had a small but statistically significant odds of LTB (pooled OR, 1.18; 95% CI, 
1.06–1.30) (67). A few studies have reported a higher frequency of TB among males 
with DM(31,68).  
Diabetics have been shown to have lesser extrapulmonary manifestations as compared to 
non-diabetics(60,69).  
There are conflicting findings on the rate of sputum positivity at the time of diagnosis of 
TB among diabetics. A study conducted in Saudi Arabia, showed that numerous Acid 
Fast Bacilli (AFB) was found in 65% of those with DM as compared to 54 % among 
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those without DM (68).  Another study conducted in Turkey, showed higher sputum 
smear positivity among diabetics (70). A study conducted in Indonesia showed a lesser 
sputum mycobacterial load among diabetics as compared to no diabetics (71). In another 
study DM was shown to have no effect on sputum mycobacterial load (62). A study from 
South Korea demonstrated a higher sputum smear positivity among uncontrolled 
diabetics (defined as HbA1c > 7) as compared to well controlled DM and non-diabetics 
with TB(72).  
A study done in Taiwan showed that 19% of Diabetics with TB had cavitatory lesions as 
compared to 10% among those without DM. This study also demonstrated the higher 
prevalence of nodular lesions on a chest X-ray among diabetics with TB(73).  A study 
done in Saudi Arabia by Shaikh et.al, demonstrated higher prevalence of lung lesions in 
the lower lung fields in diabetics as compared to non-diabetics. This study also 
demonstrated that cavitatory lung lesions were more common among diabetics and that 
DM was an independent risk factor for lung lesions or cavities in the lower lung 
fields(74). Other studies have also shown that cavitatory lung lesions and lesions in 
atypical locations(70) are more common among Diabetics with TB (75–77). A study 
conducted in South Korea found that that uncontrolled DM (defined as HbA1c > 7) was 
associated with cavitatory lung lesions and reduced culture conversion at the end of 2 
months(72). Patients with DM requiring insulin were found to have more cavitatory 
lesions as compared to non-diabetics (62).   
Effects of diabetes mellitus on treatment outcomes of tuberculosis 
There are varying reports on the effects of DM on the outcomes of TB. People with 
tuberculosis who have diabetes have a poorer response to treatment than do those without 
diabetes and are therefore at a higher risk of tuberculosis treatment failure, death, and 
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relapse after cure. Among those with active TB, TB treatment outcomes may be affected 
adversely by DM, by delaying the time to microbiological response, reducing the 
likelihood of a favourable outcome, and increasing the risk of relapse or death. The 
clinical presentation of TB in people with diabetes may be altered and change the 
sensitivity and specificity of conventional diagnostic algorithms (78). A few studies have 
showed no negative effects of DM on TB outcome like treatment failure, mortality and 
sputum culture conversion (68,72,79). 
In a systematic review of literature by Baker et.al, the pooled relative risk of treatment 
failure and death among 12 studies which looked at the outcomes of DM on TB was 1.69 
(95% CI, 1.36 to 2.12). Also the relative risk of death during treatment of TB was 1.89 
(95% CI,1.52 to 2.36) in patients with DM as compared to those without DM (80). In a 
study conducted in Taiwan, it was found that patients with diabetes-related comorbidities 
had an increased risk of unfavourable outcome  and one year mortality(64). Among 
patients with TB, DM was associated with a 5-fold risk of mortality in the first hundred 
days as compared with those not having DM. However DM did not affect long term 
mortality in this study(81). In TB patients higher treatment failure rates have been 
demonstrated among those with DM as compared without DM(82–84). Higher mortality 
rates among patients with TB and DM have been demonstrated as compared to those 
without DM (79,85,86). A meta-analysis and systemic review of the effects of DM on the 
outcomes of TB showed that among patients with TB, the risk of treatment failure or 
mortality was increased two-fold among those with DM as compared with those without 
DM (Odds ratio = 2.06, 95% CI: 1.68–2.53). Also, the Diabetics in this group had a 
higher risk of recurrence of TB as compared with the non – diabetics (Odds ratio =1.57, 
95% CI:  1.38–1.79).  
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Among patients with TB there was no effect on sputum culture conversion at 2 months or 
5 months among those with DM when compared to those without DM(81). 
 Among TB patients with DM, higher relapse rates have been shown in some 
studies(83,84,87) and a few other studies have not demonstrated any effect of DM on 
relapse rates of TB(68,88,89). Studies have shown that progression of TB is faster in 
those with DM when compared to those without DM. (12,30,50).  
A study from South India showed that the adjusted odds ratios for successful treatment of 
TB among diabetics was significantly lower than that seen in those with TB without DM 
(18). Yet another Indian study demonstrated similar findings with the mean duration for 
sputum conversion being 64.2 (± 10.5) days in patients with TB and DM as compared to 
61.5 (± 7.5) days in patients with TB without DM, which was statistically significant. 
Also the treatment failure rates were higher in the DM with TB group (4.2%) as 
compared to the TB without DM group (0.7%), which was also statistically 
significant(90).  
One study reported 14.7% sputum smear positivity  at the end of intensive phase of 
DOTS treatment among diabetics with TB and 3.6% sputum smear positivity in non-
diabetics with TB (71). Other studies do not show any relation between DM and sputum 
conversion(17,68,79). 
In a prospective study in Iran among patients with smear positive pulmonary TB and 
DM, those with poor glycaemic control (defined as HbA1c ≥ 7%) were more likely to 
have extensive lung disease, to have positive sputum smears and cavitatory lesions as 
compared to those with optimal glycaemic control (HbA1c < 7%)(91). 
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There is conflicting evidence regarding bacteriological conversion with DM in TB with 
some studies reporting slower conversion(36,82,92), with uncontrolled DM (HbA1c > 7) 
being a significant risk factor for positive sputum culture at 2 months(72).   
A study in Peru also showed that sputum culture conversion was faster among TB 
patients with glycaemic control as compared to those without optimal glycaemic 
control(93). Those with poor glycaemic control were also more likely to have positive 
sputum smears after 2 months of therapy and have higher rates of treatment failure and 
relapse(91).  
A systematic review on the effect of glycaemic control on poor outcomes in patients with 
TB and DM showed most of the studies had risk of bias but two studies which did not 
have the risk of bias showed that glycaemic control could have a favourable effect on TB 
treatment outcomes(94).  
DM has to been shown to be an independent risk factor for the development of Drug 
induced Liver Injury(95). As most of the Antitubercular drugs are Hepatotoxic, the 
incidence of drug induced Liver injury may be higher in those with DM and TB(96).  
Even though there is limited evidence on whether DM accelerates the emergence of drug 
resistant TB, especially multi drug resistant TB among those receiving TB treatment, it 
has been demonstrated in a few studies(97). However, a recently published systematic 
review and meta-analysis reported that diabetes was not associated with an increased risk 
of recurrent disease with drug-resistant TB (78). 
Other factors affecting outcomes of pulmonary tuberculosis 
Apart from Diabetes, other factors have been shown to affect the outcomes of pulmonary 
tuberculosis. A study conducted in China found that time to detection of M.tb on 
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automated liquid culture media, history of ever smoking, the presence of pulmonary 
cavitatory lesions and W-Beijing genotype were associated with delayed 2 month sputum 
culture conversion. (98) 
A historical cohort study conducted in Japan among newly diagnosed patients with 
sputum positive pulmonary tuberculosis showed that a higher smear grading and a 
history of ever smoking were associated with delayed sputum culture conversion. This 
was postulated to be related to reduced Th1 cell immunity and innate immunity 
activation along with lung T cell recruitment associated with cigarette smoke exposure 
(99,100). The association of smoking with delayed sputum culture conversion at 2 
months was also demonstrated in other prospective studies in Hong Kong and 
Brazil.(101–103). The study done in Brazil showing a dose response relationship 
between the number of cigarettes smoked daily and patients with positive sputum 
cultures after 2 months of treatment.(101)  
Studies have shown that older age, male gender, and higher bacillary load are associated 
with delayed sputum smear conversion.(104,105) Also Bilateral radiological involvement 
and Diabetes mellitus have been associated delayed sputum culture conversion(104). 
Effect of tuberculosis on diabetes mellitus  
TB, similar to other infections, can worsen glycaemic control and complicate clinical 
management of diabetes(29). Also, TB medications may interfere with the treatment of 
diabetes through drug interactions, and diabetes may interfere with the activity of certain 
anti-TB medicines. 
A study from China looking at the effects of TB on blood sugar levels, found that 
patients without DM did not develop uncontrolled sugars during TB treatment. However, 
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those newly diagnosed to have DM at the initiation of ATT, were likely to have higher 
blood sugar levels with TB treatment(106).   
In patients with pulmonary TB, glucose intolerance has been demonstrated in 16.5% to 
49% of the patients (34,44). A transient hyperglycemia has been demonstrated among 
patients with pulmonary TB. In study in Pakistan, 56% of patients on ATT who had 
glucose intolerance, which was demonstrated by an Oral glucose tolerance test (OGTT) 
had normal glucose tolerance after therapy and sputum conversion(107).  Also achieving 
optimal glycaemic control has been shown to be more difficult during the active phase of 
TB, with some patients requiring insulin for the same (34,108). 
Mechanism of hyperglycemia in tuberculosis  
 A variety of mechanisms have been thought to play a part in the hyperglycemia seen in 
TB infection. Inflammatory cytokines like Interleukin - 6 (IL-6) and TNF-α, by causing 
insulin resistance and reduced insulin production  have been implicated in the 
pathogenesis of hyperglycemia in TB (34,109).  
Drugs in the ATT regimen like Isoniazid, Rifampicin and Pyrazinamide have also been 
found to contribute to the hyperglycemia seen in TB(34,108,110–112). 
Another major contributor to worsening glycaemic control in Diabetics with TB is the 
drug interactions between Oral Anti Diabetic (OADs) agents. Sulfonylureas and 
thiazolidinediones are metabolized by cytochrome P450 (CYP) enzymes in the liver. 
Rifampicin is a potent inducer of the cytochrome P450 (CYP) enzymes. Hence plasma 
levels of OADs are lower in Diabetics with TB on Rifampicin(31,113,114). This effect of 
Rifampicin is maximally seen in the first week after starting it and is normalized within 
two weeks of stopping it(114).  Isoniazid is an inhibitor of some of these cytochrome 
P450 (CYP) enzymes. It has an inhibitory effect on CYP2C9 which is involved in the 
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metabolism of sulphonylureas. However the potent inducing effect of Rifampicin 
outweighs this inhibitory effect of Isoniazid and there is a net reduction in the plasma 
levels of sulphonylureas (115). This negative effect of Rifampicin on glycaemic control 
leads the need for higher doses of OADs like sulfonylureas and thiazolidinediones when 
used in diabetics on ATT. Also this emphasizes the need for monitoring of blood glucose 
levels in patients with DM once they are initiated on ATT(34). 
Metformin which is a Biguanide is not subject to drug interactions with Rifampicin and 
hence is a safe and the ideal OAD to be used in those with DM and TB(116).  However 
Metformin causes gastrointestinal side effects in 30 % of those on ATT(117). The other 
ideal medication for controlling DM in TB is Insulin, which is also devoid of the effects 
of rifampicin on its metabolism(34). 
 
Current recommendations for the treatment of tuberculosis and diabetes mellitus 
Studies have also shown that the time to sputum sterilization (indicated by sputum 
negativity at 2 or 3 months) is an important determinant of relapse (4–8). 
The World Health Organization and the International Union Against Tuberculosis and 
Lung Disease have recently published a collaborative framework for care and control of 
TB and DM, to address the dual challenge of DM and TB (118). 
Screening for diabetes mellitus in patients with tuberculosis 
These guidelines recommend surveillance of diabetes among TB patients in all countries. 
Surveillance for diabetes among TB patients could be by a postprandial blood glucose 
measurement with glucometer 2 hours after a meal, which is the preferred method of 
screening for diabetes in primary healthcare settings. Fasting and random blood sugars 
have a lower sensitivity in diagnosing DM. Measurement of glycated haemoglobin 
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(HbA1c) or the oral glucose tolerance test is effective but expensive and time consuming 
but are useful in confirming a glucometer reading (119).  
Screening for tuberculosis in patients with diabetes mellitus 
These guidelines advocate TB surveillance among diabetes patients in settings with 
medium to high TB burden. According to these recommendations, patients newly 
diagnosed to have DM should be asked about the presence of cough (lasting more than 2 
weeks) at the time of diagnosis and at each regular check-up for DM. 
Diagnosis and Treatment of tuberculosis in patients with diabetes mellitus 
The WHO guidelines advocate treatment and management of TB in people with diabetes 
according to the existing TB treatment guidelines and international standards. These 
guidelines also recommend the same TB treatment regimen to be prescribed to people 
with diabetes as for people without diabetes(118). The WHO now recommends daily 
dosing of ATT throughout the course of therapy in patients newly diagnosed to have TB. 
In populations known to or suspected to have high levels of isoniazid resistance, the 
WHO recommends using Isoniazid, Rifampicin and Ethambutol in the continuation 
phase as an acceptable alternative to Isoniazid and Rifampicin alone.  The WHO also 
does not advocate extension of the intensive phase of ATT in TB patients who have 
received an ATT regimen containing Rifampicin throughout treatment, if a sputum smear 
is positive found at completion of the intensive phase.  
Diagnosis of tuberculosis 
 For the diagnosis of TB, the WHO recommends the use of Nucleic acid amplification 
test - Xpert MTB/RIF as the initial diagnostic test rather than conventional microscopy, 
culture and Drug susceptibility testing in adults suspected of having multidrug resistant 
TB or HIV-associated TB. It also suggests that Xpert MTB/RIF may be used as the initial 
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diagnostic test in all adults suspected of having TB instead of conventional microscopy 
and culture in areas with adequate resources for the same. The WHO also recommends 
‘using Xpert MTB/RIF as a follow-on test to microscopy in adults suspected of having 
TB but not at risk of MDR-TB or HIV-associated TB, especially when further testing of 
smear negative specimens is necessary ‘(120). 
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METHODOLOGY 
_____________________________________________________________________ 
Institutional review board 
The institutional review board and ethics committee approved this study. The research 
funding was obtained from the fluid research grant of the institution. IRB number - 10518, 
approval date – 1.2.2017 
  
Study design 
This was a hospital based prospective observational cohort study. 
 
Study setting 
• This study was conducted in the Outpatient department and the inpatient wards of 
the Departments of General Medicine and Community health in Christian Medical 
College Hospital, a tertiary care centre in south India.  
• Patients were recruited from March 2017 to December 2017  
• The patients were followed up for a total duration of 6 months.  
 
Participants 
Inclusion Criteria  
1) Adults >/= age of 18 
2) Newly detected sputum positive Pulmonary Tuberculosis  
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3) Pre-existing/ newly detected Diabetic patients with sputum positive 
pulmonary TB 
 
Exclusion criteria  
1) Adults < age of 18 
2) HIV positive individuals 
3) Type I diabetes 
4) Pregnancy  
5) Multi drug resistant TB and Rifampin resistance on TB Xpert PCR 
 
Case definitions 
Tuberculosis case definitions 
The following case definitions were used for this study as adapted from the WHO 
definitions and reporting framework for Tuberculosis(121) 
Bacteriologically confirmed TB case:  
‘A case from whom a biological specimen is positive by smear microscopy, culture or 
WRD (such as Xpert MTB/RIF)’. 
• Clinically diagnosed TB case: 
‘A case who does not fulfil the criteria for bacteriological confirmation but 
has been diagnosed with active TB by a clinician or other medical practitioner who has 
decided to give the patient a full course of TB treatment. This definition includes cases 
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diagnosed based on X-ray abnormalities or suggestive histology and extrapulmonary cases 
without laboratory confirmation’. 
 
 
Classification based on anatomical site of disease: 
Pulmonary tuberculosis:  
‘Any bacteriologically confirmed or clinically diagnosed case of TB involving the lung 
parenchyma or the tracheobronchial tree’.  
This definition also encompasses military TB as the lesions are in the lungs.  Patients with 
pulmonary and extrapulmonary TB are classified as cases of pulmonary TB. 
Extrapulmonary tuberculosis:  
‘Any bacteriologically confirmed or clinically diagnosed case of TB involving organs 
other than the lungs, e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints 
and bones, meninges’. Patients with Tuberculous intra-thoracic lymphadenopathy or 
tuberculous pleural effusion, without radiographic abnormalities in the lungs are 
classified as cases of extrapulmonary TB.  
Classification based on history of previous tuberculosis treatment:  
New patient:  
‘A patient who has never been treated for TB or has taken anti – TB drugs for less than 
one month’. 
Previously treated patient:   
‘A patient who has received 1 month or more of anti-TB drugs in the past’.  
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These patients can be further classified based on the outcomes of their most recent course 
of ATT as:  
Relapse patients:   
‘Patients previously been treated for TB, were declared cured or treatment completed at 
the end of their most recent course of treatment and are now diagnosed with a recurrent 
episode of TB’. 
Treatment after failure patients:  
‘Patients who have previously been treated for TB and whose treatment failed at the end 
of their most recent course of treatment’. 
Treatment after loss to follow-up patients: 
‘Patients who have previously been treated for TB and were declared 
lost to follow-up at the end of their most recent course of treatment.’ 
Other previously treated patients: 
Patients who have previously been treated for TB but whose 
outcome after their most recent course of treatment is unknown or undocumented. 
Classification based on drug resistance: 
Cases are classified based on M. tuberculosis drug susceptibility testing as follows -  
Monoresistance: 
 ‘Resistance to one first-line anti-TB drug only’. 
Polydrug resistance:  
‘Resistance to more than one first-line anti-TB drug (other than both isoniazid and 
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rifampicin)’. 
Multidrug resistance:  
‘Resistance to at least both isoniazid and rifampicin’. 
Extensive drug resistance:  
‘Resistance to any fluoroquinolone and to at least one of three second-line injectable drugs 
(capreomycin, kanamycin and amikacin), in addition to multidrug resistance’. 
Rifampicin resistance: 
‘Resistance to rifampicin detected using phenotypic or genotypic methods, with 
or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, 
whether monoresistance, multidrug resistance, polydrug resistance or extensive drug 
resistance’. 
Treatment outcomes for tuberculosis patients: 
Treatment outcomes are separately defined for those with drug susceptible and drug 
resistant TB. 
Cured: 
‘A pulmonary TB patient with bacteriologically confirmed TB at the beginning of 
treatment who was smear- or culture-negative in the last month of treatment and on at 
least one previous occasion’. 
Treatment completed: 
‘A TB patient who completed treatment without evidence of failure BUT with no record 
to show that sputum smear or culture results in the last month of treatment and on at least 
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one previous occasion were negative, either because tests were not done or because results 
are unavailable’. 
Treatment failed: 
‘A TB patient whose sputum smear or culture is positive at month 5 or later during 
treatment’. 
Died: 
‘A TB patient who dies for any reason before starting or during the course 
of treatment’. 
Lost to follow-up: 
‘A TB patient who did not start treatment or whose treatment was 
interrupted for 2 consecutive months or more’. 
Not evaluated: 
‘A TB patient for whom no treatment outcome is assigned. This includes 
cases “transferred out” to another treatment unit as well as cases for 
whom the treatment outcome is unknown to the reporting unit’. 
Treatment success: 
‘The sum of cured and treatment completed’. 
 
Diabetes mellitus case definitions 
The case definitions for Diabetes mellitus have been adapted from the American Diabetic 
association definitions. (122) 
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Diabetes Mellitus is diagnosed according to the following criteria:  
 
 
Figure 3. Criteria for the diagnosis of diabetes mellitus. Adapted from Diagnosis and 
Classification of Diabetes Mellitus. Diabetes Care. 2010 Jan;33(Suppl 1):S62–9. 
 
Case ascertainment: 
Patients were recruited from the outpatient department and the inpatient wards of the 
department of General Medicine and Community health. At initial assessment, basic 
history and examination was performed and a proforma was filled by the principal 
investigator. Patients were required to give a sputum sample for AFB smear and AFB 
culture, along with blood samples for glycosylated haemoglobin and fasting and post 
prandial blood glucose levels. Demographic data and anthropometric assessment were 
also performed at this point. Baseline investigations like haemoglobin, creatinine and 
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liver enzymes were also performed at this point.  Patients were followed up at 2 months 
and if sputum AFB was negative, were followed up next at 6 months; while those with 
sputum AFB positivity at 2 monthly were followed up monthly till sputum AFB was 
negative and then at 6 months, as demonstrated in (Figure 4).  
 
Figure 4. Detailed diagrammatic Algorithm of the study 
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Pulmonary TB
Diabetics
At recruitment 
Xpert TB PCR
Sputum AFB culture
HbA1c
1st follow up - 2nd 
month  
Sputum AFB x 1
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2nd follow up -
3rd month 
Sputum AFB x1
AC,PC
Monthly follow up 
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Followup at 6 months
Sputum AFB culture
HbA1c
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Follow up at 6 
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Non 
diabetics
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Sputum AFB culture
HbA1c
1st follow up - 2nd 
month  
Sputum AFB x1
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2nd follow up - 3rd 
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AC,PC
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up till Sputum 
AFB  (-)
Followup at 6 months
Sputum AFB culture
HbA1c
Negative
Follow up at 6 
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HbA1c
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Statistical analysis: 
Sample size calculation:  
For estimating sample size for comparison of treatment outcomes among TB patients with 
and without co-morbid diabetic status, we used the following formula, 
n = {z 1-α√ [2P (1-P)] + z 1-β√ [P 1 (1-P 1 ) +P 2 (1-P 2 )]} 2 /(P 1 -P 2 ) 2 
where, P = (P 1 -P 2 )/2 
Based on a recent study in South India(123), The treatment success rate among the non-
diabetic TB patients (P 1) was assumed to be 90% (based on RNTCP accomplishments over 
the Years) The treatment success rate among the diabetic TB patients (P 2 ) was assumed 
to be 75%. With confidence level (α) of 95% and the power (1 - β) of 90%, the sample size 
needed to find difference between the two groups was estimated to be 109 in each group. 
Hence a total sample size of 220 will be recruited. 
Data analysis: 
Descriptive statistics were reported using Mean+/-SD. Frequency and percentage were 
reported for categorical variables. Chi square/Fisher's exact test were done to check the 
association between the categorical variables and the outcome variable.  
Data entry was done using EpiData software version 3.1. Statistical analysis was done 
using SPSS version 23 (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, 
Version 23.0. Armonk, NY: IBM Corp.). The treatment outcomes in the diabetic and the 
non-diabetic group were compared using students t test. P value <0.05 was considered as 
statistically significant.  
34 
 
 
RESULTS 
_____________________________________________________________________ 
 
Figure 5  Consort statement 
- 4 dead 
- 3 following up elsewhere 
- 3 not picking up calls  
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146 patients were detected to be sputum positive for AFB and were considered for 
recruitment. Among these, 16 patients were excluded for various reasons, according to 
the inclusion and exclusion criteria as shown in Figure 5. A total of 130 patients were 
recruited. Among them, 72 had DM and 58 did not have DM. Baseline characteristics 
and baseline investigations were performed for all these patients. Additionally, Sputum 
samples were sent  for Xpert TB PCR, AFB culture and sensitivity – (LJ medium / 
MGIT). All patients were started on weight-based ATT, those with elevated 
transaminases, were started on hepatosafe regimens. These patients were then followed 
up at 2 months after initiation of ATT. 41 patients with DM and 30 non-diabetics were 
assessed at 2 months of therapy. 6 patients were excluded as they had resistance to at 
least one drug. 35 patients with DM and 25 patients without DM were sputum negative at 
2 months. 6 diabetics and 5 non-diabetics were sputum positive at 2 months. These 
patients were followed up monthly till their sputum smears were negative. Among those 
with DM, 2 out of these 6 patients sputum converted at 3 months; 2 sputum converted at 
5 months, one patient was lost to follow up and one patient who was positive at 3 months 
had not reviewed at 4 months or 5 months but was sputum negative at 6 months.  
Among those without DM, who were sputum positive at 2 months, 1 patient was lost to 
follow up after 2 months. 3 patients were sputum positive at 3 months and one of these 
patients was lost to follow up after his 3-monthly evaluation. The other 2 patients were 
sputum negative after 4 months. One patient had not reviewed at 3 months but was 
sputum positive at 4 months. This patient did not follow up at 5 months but was sputum 
negative at 6 months of therapy.  
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At 6 months, 27 diabetics and 23 non-diabetics were assessed and all of them had sputum 
smears which were negative for AFB and were declared cured.  
Demographics 
Table 1.  Baseline demographic characteristics  
* Plus – minus values are means ± SD 
# Percentages in brackets 
 
Characteristics Diabetics  
(N = 68) 
Non-Diabetics  
(N = 56) 
P value  
Mean Age 
Sex (%) 
     Male  
     Female 
Area of residence (%) 
    Urban 
     Rural 
Average No. of people at home 
Average No. of rooms 
Socioeconomic status (%) 
(Modified Kuppuswamy scale) 
Upper 
Upper Middle 
Lower Middle 
Upper Lower 
Lower 
51 ± 13 
 
56 (82) 
12(18) 
 
26 (38) 
42 (62) 
5 ± 2 
2.6 ± 1 
 
 
5 (8) 
28 (41) 
28 (41) 
7 (10) 
0 
38 ± 17 
 
31 (54) 
26 (46) 
 
24 (42) 
33 (58) 
5.2 ± 2.4 
2.6 ± 0.9 
 
 
9 (16) 
21 (37) 
19 (33) 
8 (14) 
0 
0.001 
0.001 
 
 
0.602 
 
 
0.364 
0.571 
0.504 
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The Baseline demographic details were comparable among the diabetics and non-
diabetics. The mean age in the DM group was 51 years with a standard deviation (SD) of 
13. The mean age in the non-diabetic group was 31 with a SD of 17, which was 
significantly lower than the mean age in the DM group.  82 % of the diabetics were male 
while 54 % of the non-diabetics were male. 62 % of the diabetics and 58 % of the non-
diabetics were residing in rural areas. The mean number of people residing at home was 
5 with a SD of 2 in the DM group and 5.2 with a SD of 2.4 among the non-diabetics. The 
average number of rooms were 2.6 with a SD of 1 and 2.6 with a SD of 0.9 in those with 
and without DM respectively. 41 % and 37 % of diabetics and non-diabetics respectively 
belonged to the Upper middle Socioeconomic class. Lower middle class accounted for 41 
% and 33% of the diabetics and non-diabetics respectively.  
The average age was significantly higher in the DM group and had a significantly higher 
male preponderance.  
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Figure 6. Income of patients 
 
48 % of the diabetics had an income between Rs. 7600 and Rs. 10132. 28 % of the non-
diabetics had an income between Rs. 10133 and Rs. 20, 265.  
 
Figure 7. Occupation of patients 
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The most common occupation among those with DM was Clerical or owning a shop or 
farming - accounting to 35%. Clerical or owning a shop or farming was the occupation in 
25 % of the non-diabetics. There was no significant difference between the occupational 
status of both groups  (p value – 0.480). 
 
 
Figure 8. Educational status of patients  
 
38 % and 33 % of diabetics and non-diabetics respectively had attended high school. 23 
% of those DM had attended an intermediate school and 26 % of the non-diabetics had a 
graduate or post graduate degree. There was no significant difference in the educational 
status of both groups  (p value – 0.649).  
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Clinical characteristics 
Table 2. Clinical characteristics of patients (%) 
Characteristics Diabetics  
(N = 68) 
Non-Diabetics 
(N = 56) 
P value 
Symptoms 
Fever 
Cough 
Expectoration 
Haemoptysis 
Chest Pain 
Breathlessness 
Loss of Appetite 
Loss of Weight 
Past TB 
Outcomes of previous TB 
    Cured 
    Treatment after failure patients 
Extrapulmonary TB 
Sites of EPTB 
TB meningitis 
TB Lymphadenitis 
Abdominal TB 
Bone marrow TB 
Hypertension 
 
56 (82) 
68 (100) 
60 (88) 
6 (9) 
3 (4) 
33 (49) 
58 (85) 
52 (77) 
4 (6) 
 
2 
2 
 
6 (9) 
6 
1 
0 
0 
26 (38) 
 
44 (77) 
56 (98) 
51 (90) 
5 (9) 
2 (3) 
19 (33) 
59 (86) 
39 (68) 
5 (9) 
 
4 
1 
 
11 (19) 
5 
4 
1 
1 
7 (12) 
 
0.442 
0.452 
0.854 
1.00 
1.00 
0.101 
0.947 
0.286 
0.730 
0.524 
 
 
0.081 
 
 
 
 
 
0.001 
*Percentages in brackets 
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Clinical characteristics of patients continued. 
Characteristics Diabetics 
(N = 68) 
Non-Diabetics 
(N = 56) 
P value 
Hypothyroidism 
Chronic liver disease 
Chronic kidney disease 
COPD 
Smoking 
No. of pack years 
Ethanol consumption 
Height 
Weight 
BMI 
3 (4) 
3 (4) 
6 (9) 
4 (6) 
28 (41) 
13 
21 (31) 
164.4 ±7.7 
55 ± 11.2 
20.4 ± 4 
4 (7) 
2 (4) 
3 (6) 
2 (4) 
13 (23) 
8.2 
5 (9) 
161 ± 9 
46 ± 11.7 
17.9 ± 3.7 
0.700 
1.000 
0.511 
0.689 
0.019 
0.335 
0.003 
0.21 
0.001 
0.001 
*Percentages in brackets 
# Plus – minus values are means ± SD 
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Table 3. Clinical characteristics of Diabetics (%) 
Characteristics  Frequencies 
Duration  
   Newly diagnosed DM 
Treatment modality for DM  
   OHAs 
   Insulin 
   Insulin and OHAs 
   Medical nutrition therapy 
Complications of DM 
   Neuropathy 
   Nephropathy 
   Retinopathy 
   IHD 
   CVA 
   PVD 
Hba1c (initial) 
Uncontrolled DM (HbA1c > 7) 
AC 
PC 
Hba1c (6 months) 
5.6 
6 (9) 
 
50 (73) 
12(18) 
4 (6) 
2 (3) 
 
20 (29) 
18 (26) 
12 (18) 
5 (7) 
3 (4) 
2 (3) 
9.5  
50 (75) 
143 ± 19 
266 ± 33 
7.7 
*Percentages in brackets 
# Plus – minus values are means ± SD 
Most of the baseline characteristics were similar in both the groups. There was no 
significant difference in the symptoms at presentation like fever, cough, expectoration, 
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haemoptysis, chest pain, breathlessness, loss of appetite, loss of weight among the 
diabetics and the non-diabetics. 6 % of the diabetics and 9 % of the non-diabetics had a 
past history of having tuberculosis, which was not statistically significant. Those with a 
past history of TB were either cured or had failure of treatment and there was no 
difference in the frequencies of these among both the groups. Though the rates of 
extrapulmonary TB was more among the non – diabetics, this difference was not 
statistically significant. TB lymphadenitis was more common among the non – diabetics. 
In the DM group, 9% were newly diagnosed to have DM. Nearly 70 % of the diabetics 
were on oral diabetic agents and 18 % were on insulin. The most common microvascular 
complication was diabetic neuropathy which was seen in around 30% of the patients. 
Ischaemic heart disease was the most common macrovascular complication which was 
seen in 7% of the patients. 
38 % of the diabetics had hypertension while only 12% of the non-diabetics had 
hypertension and this difference was statistically significant. There was no significant 
difference in the frequencies of other co morbidities like  hypothyroidism, chronic liver 
disease, chronic kidney disease and chronic obstructive pulmonary disease among the 
diabetics and the non – diabetics.  
Smoking frequency was more in the diabetics as compared with the non – diabetics and 
this was statistically significant. However, there was no significant difference in the 
mean number of pack years between the two groups. Ethanol consumption was also 
higher among the diabetics as compared to the non – diabetics and this difference was 
statistically significant. However, there was no significant difference between the mean 
duration of ethanol consumption between the groups. There was a significant difference 
in the weight and BMI of the patients with and without DM, with the non – diabetics 
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having lower weights and BMIs. The mean BMI among the non – diabetics was 17.9. 57 
% of the non - diabetics were underweight while only 26 % were underweight among the 
diabetics. This difference was statistically significant.   
 
Figure 9. Frequency of Extrapulmonary Tuberculosis 
 
6 patients (9%) and 11 patients (19%) of the patients had extrapulmonary TB along with 
pulmonary TB among those with and without DM respectively. Among the diabetics, 5 
patients had TB meningitis and one patient had TB meningitis and TB lymphadenopathy. 
Among the Non-diabetics, 5 had TB meningitis, 4 had TB lymphadenitis, 1 patient had 
abdominal TB and 1 patient had bone marrow infiltration of TB.  
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Investigations 
 
Table 4. Laboratory features of patients 
Characteristics  Diabetics  
(n = 68) 
Non-Diabetics  
(n = 56) 
P value 
Haemoglobin 
Creatinine 
Albumin  
SGOT 
SGPT 
Hba1c 
AC 
PC 
Sputum AFB 
Negative 
Scanty 
1+ 
2+ 
3+ 
11.8 ± 2.4 
1.0 
3.3 ± 0.7 
32 
25 
9.5 ± 2.5 
143 ± 19 
266 ± 33 
 
10 (15) 
6 (9) 
25 (37) 
18 (26) 
9 (13) 
10.8 ± 2.5 
0.8 
3.0 ± 0.8 
38 
29 
5.3 ± 0.5 
89 ± 8 
127 ± 37 
 
15 (26) 
5 (9) 
9 (16) 
11 (19) 
17 (30) 
0.026 
0.134 
0.038 
0.466 
0.472 
0.001 
0.001 
0.002 
 
 
 
 
 
0.02 
*Percentages in brackets 
# Plus – minus values are means ± SD 
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Table 5. Chest X-ray findings (%) 
Chest X-ray findings Diabetics 
 (n = 68) 
Non-Diabetics  
(n = 56) 
Normal  10 (15) 16 (29) 
Consolidation 26 (38) 17 (30) 
Milliary mottling 9 (13) 6 (12) 
Fibrocavitatory changes  17 (25) 12 (22) 
Reticulonodular opacities 6 (9) 4 (7) 
*Percentages in brackets 
Haemoglobin levels were significantly lower in the non-diabetics when compared with 
the diabetics. The mean albumin levels were lower than normal in both the groups 
(Normal  albumin levels- 3.5- 5.5 in our institution) and the albumin levels were 
significantly lower in the non-diabetics. The mean HbA1c was 9.5 in the DM group and 
5.3 in the NDM group. 
The non – diabetics had a slightly higher percentage of patients with a normal chest X 
ray. Consolidation was the most common X ray finding in both the groups. There was no 
significant difference between the chest X ray findings in both the groups. 7% of patients 
with cavities were using insulin. However, there was no significant association between 
the two (p value – 0.49).  
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Sputum characteristics of patients 
 
Figure 10. Quantification of Sputum AFB smears at recruitment 
15 % of the diabetics had negative sputum smears while 27 % had negative smears 
among the non-diabetics. Scanty AFB was seen in 9% of the sputum smears in both 
diabetics and non-diabetics. 1+ AFB was seen in 37 % of the sputum smears of the 
diabetics whereas it was 16 % among the non – diabetics. 26% of the diabetics and 18% 
of the non- diabetics had 2+ AFB in sputum smears. The non – diabetics had a 
significantly higher bacillary load as compared with the diabetics. Among the 9 patients 
with a high bacillary load in the DM group, HbA1c levels were available for 8 of the 
patients and all of them had uncontrolled Dm (HbA1c > 7). There was no significant 
association between patients with HbA1c > 9 and high bacillary load (p value – 0.71) 
90% (61) of the diabetics had given sputum for AFB culture while 82 % (46) of the non – 
diabetics had given sputum for AFB culture. 81 % of the sputum cultures of diabetics 
grew M. Tb, while in 9% sputum cultures did not show any growth and 10 % had not 
given samples for AFB culture.  
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61 % of the sputum cultures of the non - diabetics grew M. Tb, while in 21 % sputum 
cultures did not show any growth and 18 % had not given samples for AFB culture. 
Patients who had grown resistant strains or showed Rifampin resistance on Xpert Tb 
PCR were excluded from the study. Those patients who had neither given sputum 
samples for Xpert TB PCR or for AFB cultures were also excluded.  
93% of the Diabetics gave sputum samples for Xpert TB PCR testing and among them, 
100 % had a positive result.  
95% of the non - diabetics had given sputum samples for Xpert TB PCR testing and 
among these, 91 % had a positive result while 4 % had a negative result and 5% of the 
patients had not given sputum samples.  
Drug induced Liver injury 
 
 
Figure 11. Dug Induced Liver injury in patients  
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Drug induced Liver injury (DILI) was slightly more common in the non-diabetic group. 
However, there was no statistically significant difference in the percentages of DILI in 
both the groups.  
Effect of Treatment of TB on glycaemic control 
 
Figure 12. Variation in Hba1c at enrolment and at 6 months  
 
The mean Hba1c at enrolment among those with DM was 9.5 %, which had reduced to 
7.8 at 6 months. However only 27 patients with DM had followed up at 6 months.  
While, the mean Hba1c was 5.4 % at enrolment and at 6 months among those without 
DM, where 23 patients had followed up. The reduction in HbA1c in the DM group with 
the treatment of TB was significant [ p value – 0.001, mean difference – 1.76, 95% CI of 
difference – (1.01 – 2.52)]  
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Delayed sputum conversion 
 
 
Figure 13. Sputum smear positivity at 2 months 
 
41 patients with DM had followed up at 2 months and among them 6 patients (15%) were 
sputum positive.  28 non – diabetic patients had followed up at 2 months and among 
them 5 patients (18%) were sputum positive.  
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Table 6. Characteristics of delayed sputum convertors who were diabetics 
Patient serial No.  1 2 3 4 5 6 
Age 36 60 74 67 40 54 
Sex male female male male male male 
Prior TB No No No No No No 
Duration of DM  
(in years) 
1 10 15 10 6 3 
Treatment of DM OHA OHA OHA OHA OHA OHA 
Microvascular 
complications 
No  Yes Yes Yes No No 
Macrovascular 
complications 
No No Yes No No No 
Extrapulmonary TB No No No No No No 
Chronic Kidney 
Disease 
No No No No No No 
Chronic Liver 
Disease 
No No No No No No 
COPD No No Yes No No Yes 
Hypothyroidism No No No Yes  No  No 
Hypertension No No Yes Yes No No 
Smoking Yes No  Yes  Yes  Yes  Yes  
Packyears 2 NA 35 15 5 20 
Ethanol consumption No  No Yes  Yes  Yes  No 
Duration in years NA NA 15 10 10 NA 
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Characteristics of delayed sputum convertors who were diabetics continued 
Patient serial No.  1 2 3 4 5 6 
Weight (Kg) 43 65 68 49 44 50 
BMI  15.8 27 25.00 21.50 18.00 22.20 
Sputum smears ++ +++ ++ + +++ ++ 
HbA1c 10.9 11.4 6.0 8.2 7.5 6.9 
Haemoglobin 13.6 9.6 9.1 12.7 7.8 14.3 
Creatinine 1.2 1.1 0.6 0.6 0.7 0.8 
SGOT 26 24 17 33 75 NA 
SGPT 16 24 14 40 46 NA 
Albumin 3.0 3.4 3.10 3.10 2.70 4.60 
AFB culture Positive  Positive Positive Positive NA Positive 
Sensitivity Sensitive Sensitive Sensitive Sensitive NA Sensitive 
Xpert TB PCR Positive Positive Positive Positive Positive Positive 
Rifampin resistance No No No No No No 
Chest X ray findings 
Fibro 
cavitatory 
changes 
Consolidation 
Fibro 
cavitatory 
changes 
Fibro 
cavitatory 
changes 
Milliary 
mottling 
consolidation 
Weight at 2 months 45 64 68 50 48 51 
AFB smear - 2months Scanty + Scanty + Scanty Scanty 
AC - 2months 159 437 118 113 157 111 
PC - 2months 315 601 150 153 249 244 
DILI* No  No  No  No  No  No  
*DILI – Drug induced Liver Injury  
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Characteristics of delayed sputum convertors who were diabetics continued 
Patient serial No.  1 2 3 4 5 6 
Assessment at 3 months No Yes Yes No Yes Yes 
Weight at 3 months NA 64 70 NA 49 52 
AFB smear - 3 months NA ++ + NA Negative Negative 
AC at 3 months NA 272 NA NA 120 NA 
PC at 3 months NA 241 NA NA 180 NA 
Hba1c at 3 months NA NA 6.1 NA NA 7.0 
Assessment at 4 months No No No Yes No No 
Weight at 4 months NA NA NA 52 NA NA 
AFB smear - 4 months NA NA NA ++ NA NA 
AC - 4 months NA NA NA 120 NA NA 
PC - 4 months NA NA NA 170 NA NA 
Hba1c - 4 months NA NA NA NA NA NA 
Assessment at 5 months Yes Yes No No No 
 
No 
 
Weight at 5 months 46 65 NA NA NA NA 
AFB smear - 5 months Negative  Negative  NA NA NA NA 
AC - 5 months 104 229 NA NA NA NA 
PC - 5 months 146 149 NA NA NA NA 
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Characteristics of delayed sputum convertors who were diabetics continued 
Patient serial No.  1 2 3 4 5 6 
Assessment at 6 
months 
Yes Yes Yes No Yes No 
Weight at 6 months 48 66 66 NA 50 NA 
AFB smear - 6 
months 
Negative  Negative  Negative  NA Negative NA 
AFB culture at 6 
months 
NA Negative  Negative  NA Negative NA 
Treatment outcome Cured Cured Cured 
Not 
evaluated 
Treatment 
completed 
Treatment 
completed 
Hba1c at 6 months 6.1 9.7 5.9 NA 7.0 NA 
 
There were 6 patients with DM who were sputum positive at 2 months. Their 
characteristics have been described in (Table 6). The mean age of these patients was 55 
years. The majority of these patients were male. 5 out of the 6 patients had a history of 
smoking. The mean weight of the patients was 53 Kgs and the mean BMI was 21.6 
Kg/m2. The mean Haemoglobin level was 11.2 g/dL in this group and the mean albumin 
was 3.3 g. The mean duration of DM was 7.5 years with a mean HbA1c of 8.5. 4 out of 
these 6 patients had followed up at 6 months. 3 of the 6 patients had microvascular 
complications of DM while only 1 patient had macrovascular complications.  
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Table 7. Characteristics of Delayed sputum convertors who were non-diabetics 
Patient serial No.  1 2 3 4 5 
Age 29 54 33 55 58 
Sex male male female male female 
Prior TB No No 
Yes - 
defaulted 
No No 
Extrapulmonary TB No No No No No 
Chronic Kidney 
Disease 
No No No No No 
Chronic Liver Disease No No No No No 
Chronic Obstructive 
Pulmonary Disease 
No Yes No No No 
Hypothyroidism No No No No No 
Hypertension No No No No No 
Smoking Yes Yes No Yes No 
Packyears 8 15 NA 5 NA 
Ethanol consumption Yes No No No No 
Duration in years 5.0 NA NA NA NA 
Weight (Kg) 40 55 38 64 50 
BMI  15.2 20.4 15.60 23.10 21.10 
Sputum smears +++ +++ +++ +++ +++ 
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Characteristics of delayed sputum convertors who were non - diabetics continued 
Patient serial No.  1 2 3 4 5 
HbA1c 5.3 5.9 5.4 5.4 NA 
Haemoglobin 10.0 15.4 11.6 NA 12.1 
Creatinine 0.8 1.2 0.7 0.9 0.6 
SGOT 260 34 17 NA 20 
SGPT 288 30 24 NA 9 
Albumin 2.9 3.5 2.70 2.80 3.00 
AFB culture No growth* Positive Positive Positive NA 
Sensitivity NA Sensitive Sensitive Sensitive NA 
Xpert TB PCR Positive Positive Positive Positive Positive 
Rifampin resistance No No No No No 
Chest X ray findings Consolidation Consolidation 
Fibro 
cavitatory 
changes 
Consolidation 
Fibro 
cavitatory 
changes 
Weight at 2 months 39 60 40 67 53 
AFB smear – 2 months 4 4 1 4 4 
DILI Yes No No No No 
Assessment at 3 months No No Yes Yes Yes 
Weight at 3 months NA NA 40 67 54 
AFB smear - 3 months NA NA + Scanty Scanty 
Assessment at 4 months Yes No No No No 
Weight at 4 months 39 NA NA NA NA 
AFB smear - 4 months ++ NA NA NA NA 
*DILI – Drug Induced Liver Injury 
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Characteristics of delayed sputum convertors who were non - diabetics continued 
Patient serial No.  1 2 3 4 5 
Assessment at 5 months No No No No No 
Weight at 5 months NA NA NA NA NA 
AFB smear - 5 months NA NA NA NA NA 
Assessment at 6 months Yes No No Yes Yes 
Weight at 6 months 41 NA NA 68 55 
AFB smear - 6 months Negative NA NA Negative Negative 
AFB culture at 6 months Negative NA NA Negative Negative 
Treatment outcome 
Treatment 
completed 
Not 
evaluated 
Not 
evaluated 
Treatment 
completed 
Treatment 
completed 
Hba1c at 6 months 5.6 NA NA 5.4 5.6 
*Sputum sample for AFB culture was given 1 month after initiation of ATT.     
Subsequent sputum smears were positive, but cultures were negative 
 
There were 5 patients without DM who were sputum positive at 2 months. Their 
characteristics have been described in (Table 7). The mean age of these patients was 46 
years. The majority of these patients were male. Only 1 out of the 6 patients had a history 
of smoking. The mean weight of the patients was 49 Kgs and the mean BMI was 19.1 
Kg/m2.  The mean Haemoglobin level was 12.3 g/dL in this group and the mean albumin 
was 2.9 g. 3 out of these 6 patients had followed up at 6 months.  
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Table 8. Factors influencing delayed sputum conversion 
Parameters  Sputum 
positive  
at 2 months 
Sputum 
negative  
at 2 months 
p Value 
Relative risk  
(95% CI) 
Diabetes  
   Diabetics 
   Non-diabetics 
 
6 
5 
 
35 
28 
0.71 0.78 (0.21 to 2.89) 
Sex 
   Male 
   Female 
 
8 
3 
 
38 
20 
0.64 1.4 (0.34 to 5.89) 
Past Tuberculosis 
   Yes 
   No 
 
1 
10 
 
4 
54 
0.79 1.35 (0.14 to 13.36) 
COPD 
   Yes 
   No 
 
3 
8 
 
1 
57 
0.001 21.3 1.97 to 231.21) 
Smoking  
   Yes 
    No 
 
8 
3 
 
10 
48 
0.0001 12.8 (2.89 to 56.89) 
Ethanol 
consumption 
   Yes 
    No 
 
 
4 
7 
 
 
10 
48 
0.15 2.74 (0.67 to 11.17) 
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Factors influencing delayed sputum conversion continued 
Parameters Sputum 
positive  
at 2 months 
Sputum 
negative 
at 2 months 
p Value 
Relative risk 
(95% CI) 
Underweight  
   Yes 
    No 
 
4 
7 
 
27 
31 
0.53 0.7 (0.17 to 2.48) 
Cavitatory lesions 
    Yes 
    No 
 
5 
6 
 
8 
50 
0.014 5.2 (1.29 to 21.16) 
Anemia 
   Yes 
    No 
 
7 
4 
 
35 
23 
0.84 1.15 (0.30 to 4.38) 
Hypoalbuminemia 
   Yes 
    No 
 
9 
2 
 
31 
26 
0.09 3.7 (0.74 to 19.04) 
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Factors influencing delayed sputum conversion continued 
Parameters  Sputum 
positive 
 at 2 months 
Sputum 
negative  
at 2 months 
p Value 
Relative risk  
(95% CI) 
High Bacillary load 
   Yes 
    No 
 
7 
4 
 
7 
51 
0.001 12.75 (2.96 to 
54.93) 
DILI 
   Yes 
   No 
 
1 
10 
 
8 
50 
0.67 0.67 (0.07 to 5.57) 
Uncontrolled DM 
    Yes 
     No 
 
4 
2 
 
26 
8 
0.61 0.67 (0.09 to 4.01) 
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Table 9. Factors influencing delayed sputum conversion in diabetics and non-diabetics 
Parameters  p Value Relative risk (95% CI) 
Male Sex 
   Diabetics    
   Non-diabetics 
 
0.87 
0.30 
 
0.8 (0.08 to 8.71) 
2.81 (0.38 to 20.46) 
Past Tuberculosis* 
   Diabetics    
   Non-diabetics 
 
NA 
0.21 
 
NA 
5.5 (0.28 to 107.15) 
COPD 
   Diabetics    
   Non-diabetics 
 
0.001 
0.21 
 
9.75 (3.85 to 24.67) 
3.25  (0.28 to 107.15) 
Smoking  
   Diabetics    
   Non-diabetics 
 
0.002 
0.02 
 
20 (2.01 to 199.73) 
10 (1.15 to 86.87) 
Ethanol consumption 
   Diabetics    
   Non-diabetics 
 
0.227 
0.218 
 
2.87 (0.49 to 16.97) 
5.5 (0.28 to 107.15) 
Underweight 
   Diabetics    
   Non-diabetics 
 
0.813 
0.141 
 
1.2 (0.19to 7.94) 
0.23 (0.03 to 1.77) 
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Factors influencing sputum conversion in diabetics and non-diabetics continued 
Cavitatory lesions 
   Diabetics    
   Non-diabetics 
 
0.02 
0.264 
 
7.7 (1.14 to 52.29) 
3.2 (0.39 to 25.57) 
Anemia  
   Diabetics    
   Non-diabetics 
 
0.413 
0.393 
 
2.1 (0.34 to 13.09) 
0.4 (0.05 to 3.22) 
Hypoalbuminemia  
   Diabetics    
   Non-diabetics 
 
0.13 
0.418 
 
5 (0.52 to 47.43) 
2.6 (0.25 to 26.85) 
DILI# 
   Diabetics    
   Non-diabetics 
 
NA 
0.89 
 
NA 
1.15 (0.11 to 13.65) 
High bacillary load$ 
   Diabetics    
   Non-diabetics 
 
0.87 
NA 
 
5.33 (0.67 to 42.2) 
NA 
* No past history of Tb in diabetics; #No DILI in diabetics; $All non-diabetics had high 
bacillary load 
 
COPD had a significant effect on delayed sputum smear conversion in patients with 
pulmonary TB and this effect was also demonstrated in the diabetic sub group. Smoking 
also had a significant effect on delayed sputum smear conversion in patients with 
pulmonary TB and this effect was also demonstrated in the diabetic and non-diabetic sub 
groups. The presence of fibrocavitatory lesions was associated with delayed sputum 
smear conversion in the entire group of patients and in the diabetic sub group. There was 
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a significant association between bacillary load and delayed sputum conversion in the 
entire study group and this was demonstrated in the NDM group as 100 % of the delayed 
convertors in the NDM group had a high bacillary load. 
 
There was no significant association between DM and sputum smear conversion. 
Uncontrolled DM also did not have any significant effect on delayed sputum conversion. 
There was no association which could be demonstrated between Ethanol consumption, 
past history of TB, being underweight, anemia, hypoalbuminemia, Drug induced Liver 
Injury  and delayed sputum conversion.  
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Mortality 
Table 10. Cause of death in patients with fatal outcomes 
No. Age Cause  
Day (From 
diagnosis) 
Significant 
comorbidities 
1.  22 
Aspiration 
Pneumonia 
29 
TBM – MRC III 
Coma Vigil 
 
2.  56 
Diabetic Ketoacidosis 
(DKA) with septic 
shock 
4 
Klebsiella 
Pneumonia, DM 
3.  52 
Acute Liver Failure – 
ATT DILI, 
Refractory 
Hypotension 
18 
Renal Allograft 
recipient, Oliguric 
Renal Failure 
4.  29 
Type 1 DM with 
DKA, Hospital 
Acquired Pneumonia 
NA (Died in 
another centre) 
DILI, DM 
5.  49 
Hyperglycaemic 
Hyperosmolar State, 
Candidemia 
20 
Type 2 DM with poor 
glycaemic control 
6.  71 
Acute Coronary 
Syndrome 
26 
Aspiration 
Pneumonia, TBM – 
MRC III, DM 
7.  59 DKA, Septic Shock 3 
Invasive Rhino 
cerebral 
Mucormycosis, DM 
8.  68 
Acute Coronary 
Syndrome (ACS) 
4 Rheumatoid Arthritis 
9.  69 GNB Sepsis 20 Recent ACS, DM 
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Cause of death in patients with fatal outcomes continued 
No. Age Cause  
Day (From 
diagnosis) 
Significant 
comorbidities 
10.  65 
Septic Shock with 
oliguric renal failure 
7 T2DM 
11.  56 NA NA 
Non-Hodgkin 
Lymphoma, DM 
12.  54 
Candidemia with 
Septic Shock 
24 T2DM 
13.  46 
Hyperglycaemic 
Hyperosmolar state 
with septic Shock 
3 
Acute Respiratory 
Distress Syndrome, 
T2DM 
14.  64 NA NA 
Hilar 
Cholangiocarcinoma 
 
14 patients had fatal outcomes. 10 patients died during their hospital stay, 2 patients died 
during the intensive phase and 2 during the continuation phase of ATT. 10 were diabetics 
and 4 were non – diabetics. The associated co morbidities in the patients have been 
described in (Table 20).  
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Table 11. Characteristics of patients with fatal outcomes 
Parameters 
Patients with 
Fatal outcomes  
Patients with non-
fatal outcomes  
p Value 
Relative risk, 
(95% CI) 
Diabetes 
     Yes 
      No 
 
10  
4 
 
58  
52 
0.257 2.1 (0.68-7.58) 
Prior TB 
     Yes 
      No 
 
2 
12 
 
7 
103 
0.27 2.4 (0.45 – 13.17) 
Extrapulmonary 
TB 
    Yes 
     No 
 
4 
10 
 
13 
97 
0.1 
 
2.9 (0.82 – 10.91 
 
Smoking 
    Yes 
     No 
 
7 
7 
 
33 
77 
0.13 
 
2.3 (0.76 – 7.18) 
 
Hypertension 
    Yes 
     No 
 
7 
7 
 
25 
85 
0.06 
 
3.4 (1.09 – 10.62) 
 
CKD 
    Yes 
     No 
 
4 
10 
 
5 
105 
0.001 
 
8.4 (1.99– 36.39) 
 
IHD 
    Yes 
     No 
 
2 
12 
 
3 
107 
0.03 
 
5.9 (1.19- 13.17) 
 
COPD 
    Yes 
     No 
 
2 
12 
 
4 
106 
0.08 
 
4.4 (0.73 – 26.7) 
 
Anemia 
    Yes 
     No 
 
13 
1 
 
69 
41 
0.02 
 
 
7.7 (0.97 – 61.24) 
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Characteristics of patients with fatal outcomes continued 
Parameters 
Patients with 
Fatal outcomes  
Patients with non-
fatal outcomes  
p Value 
Relative risk, 
(95% CI) 
Under weight 
    Yes 
     No 
 
6 
8 
 
46 
64 
0.9 
 
1.1 (0.39 – 3.21) 
 
Uncontrolled DM 
    Yes 
     No 
 
7 
3 
 
43 
13 
0.64 0.70 (0.16 – 3.12) 
 
DILI 
    Yes 
     No 
 
3 
11 
 
11 
99 
0.19 
 
2.4 (0.59 – 10.16) 
 
High Bacillary 
load 
    Yes 
     No 
 
 
1 
13 
 
 
25 
85 
0.29 0.2 (0.04 – 2.09) 
Mean Age 53.7 ± 17.2 44.3 ± 16.5 0.04 (7.68 – 18.81)# 
Mean BMI 
 
19.20 ± 4.3 19.27 ± 4.0 0.94 
 
(1.11 – 3.87) # 
Mean Weight     
 
53.2 ± 12.6 50.8 ± 11.9 0.48 
 
(4.52 – 12.59) # 
Mean Albumin     
 
2.6 ± 0.7 3.2 ± 0.7 0.01 (0.01 – 0.55) # 
Mean Hba1c     
 
8.3 ± 2.8 7.8 ± 2.8 0.54 (3.39 – 4.95) # 
Mean 
Haemoglobin 
 
10.4 ± 1.9 11.4 ± 2.5 0.14 (-2.39 – 0.36) # 
Mean Creatinine    
 
2.1 ± 2 0.8 ± 0.3 0.001 (-0.07 – 0.56) # 
* Plus – minus values are means ± SD; #95% CI of  difference of means 
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Table 12. Factors contributing to mortality in diabetics and non-diabetics  
Parameters p Value Relative risk, (95% CI) 
Prior TB 
   Diabetics 
   Non-diabetics@ 
            
0.1 
NA 
 
7 (0.86 – 56.89) 
NA 
Extrapulmonary TB 
   Diabetics 
   Non-diabetics 
 
0.21 
0.17 
 
3.4 (0.53 – 21.52) 
4.1 (0.65 – 25.9) 
Smoking 
   Diabetics 
   Non-diabetics* 
 
0.08 
NA 
 
4.11 (0.96 – 17.61) 
NA 
Hypertension 
   Diabetics 
   Non-diabetics 
 
0.48 
0.05 
 
1.6 (0.45 – 6.78) 
12 (1.31 – 109.33) 
CKD 
   Diabetics 
   Non-diabetics 
 
0.003 
0.20 
 
7.8 (1.32 – 46.73) 
5.9 (0.84 – 41.04) 
IHD 
   Diabetics 
   Non-diabetics# 
 
0.15 
NA 
 
4.5 (0.67 – 31.78) 
NA 
COPD 
   Diabetics 
   Non-diabetics$ 
 
0.1 
NA 
 
4 (0.86 – 56.89) 
NA 
Anemia 
   Diabetics 
   Non-diabetics& 
 
0.04 
NA 
 
7.3(0.87 – 61.52) 
NA 
Under weight 
   Diabetics 
   Non-diabetics 
 
0.46 
0.77 
 
1.7 (0.43 – 7.03) 
0.7 (0.09 – 5.61) 
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Factors contributing to mortality in diabetics and non-diabetics continued 
DILI 
   Diabetics 
   Non-diabetics 
 
 
0.27 
0.43 
 
2.6 (0.44 – 16.04) 
2.5 (0.28 – 28.67) 
Mean BMI 
   Diabetics 
   Non-diabetics 
 
 
0.52 
0.92 
 
(-3.57 – 1.84) ^ 
(-3.75 – 4.13) ^ 
Mean Weight 
   Diabetics 
   Non-diabetics 
 
 
0.98 
0.64 
 
(-7.78 – 7.62) ^ 
(-9.16 – 14.74) ^ 
Mean Albumin 
   Diabetics 
   Non-diabetics 
 
 
0.06 
0.02 
 
(-0.92 to 0.02) ^ 
(-1.69 – -0.11) ^ 
Mean Hba1c 
   Diabetics 
   Non-diabetics 
 
 
0.65 
0.81 
 
(-2.17 – 1.37) ^ 
(0.58 – 0.73) ^ 
Mean Haemoglobin 
   Diabetics 
   Non-diabetics 
 
 
0.11 
0.45 
 
(-2.91 – 0.28) ^ 
(-3.01 – 0.39) ^ 
Mean Creatinine 
   Diabetics 
   Non-diabetics 
 
 
0.001 
0.03 
 
(0.92 – 2.30) ^ 
(0.05 – 0.85)^ 
@No history of past TB among the non-diabetics; *No smokers among the non-diabetics 
#No IHD in the non-diabetic group;$No COPD in the non-diabetic group; 
&All patients in the non-diabetic group had anemia; ^ 95% CI of difference of means 
70 
 
 
There was a significant association between Creatinine levels, the presence of CKD and 
mortality in the entire study group and in the DM, NDM sub groups. Ischaemic heart 
disease and a lower mean weight were associated with mortality in the entire population. 
Anemia was associated with mortality in the entire study group and in the DM sub-
group. Low albumin levels were associated with mortality in the entire study group and 
in the non-diabetic sub group. Hypertension was significantly associated with Mortality 
in the NDM sub group. However, in the entire study population, there was no association 
between hypertension, smoking, COPD and fatal outcomes.  
 
Multivariate analysis  
 
Delayed sputum conversion 
Table 13. Multivariate analysis for factors affecting sputum conversion  
Parameters p Value Adjusted Odds ratio, (95% CI) 
Cavitatory lung lesions  0.05 6.7 ( 1.01 to 45.61) 
COPD 0.006 60.1 (3.23 to 1116.47) 
High bacillary load 0.001 22.5 (3.34 to 151.21) 
 
Cavitatory lung lesions, COPD and a high bacillary load   were significantly associated 
with delayed sputum conversion.  Smoking was significantly associated with delayed 
sputum conversion on a univariate analysis.  
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Mortality 
Table 14. Multivariate analysis for factors affecting sputum conversion 
Parameters p Value Adjusted Odds ratio, (95% CI) 
IHD  0.14 5.2 ( 0.56 to 47.97) 
Albumin 0.02 3.5 (1.24 to 9.94) 
High bacillary load 0.16 22.5 (3.34 to 151.21) 
CKD 0.03 6.1 (1.11 to 33.5) 
Anemia 0.26 3.5 (0.39 to 32.21) 
 
On logistic regression, lower albumin levels and CKD were significantly associated with 
mortality. IHD, high bacillary load and anemia did not influence mortality.  
 
Treatment outcomes  
 
Table 15. Treatment outcomes 
Treatment outcomes  Diabetics 
 (N = 68) 
Non-Diabetics  
(N = 56) 
Cured  
Treatment completed 
Died 
Not Evaluated  
17 (25) 
22 (32) 
10 (15) 
19 (28) 
14 (25) 
14 (25) 
4 (7) 
24 (43) 
*Percentages in brackets 
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Out of the 27 diabetics had followed up at 6 months, 9 were unable to give sputum 
samples as they did not have expectoration. Hence their outcomes were, in accordance 
with the WHO case definitions taken as treatment completed. Similarly, in the NDM 
group 23 patients followed up at 6 months and 6 did not give sputum samples as they 
were unable to expectorate, and their outcomes were taken as treatment completed. 
Patients who were sputum negative at any point of time before the 5th month and had not 
followed up at 6 months, were taken as treatment completed as per the WHO case 
definitions. There was no significant association between treatment completion or cure in 
both the groups and DM [p value - 0.47, RR– 1.14, 95 % CI – (0.83 – 1.6)]. 57 % in the 
DM group and 50 % in the NDM group were either cured or had completed treatment 
successfully.  
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DISCUSSION 
_____________________________________________________________________ 
In this prospective observational cohort study, we aimed to look at the effect of DM on 
the outcomes of sputum positive pulmonary TB. We wished to look at the cure rates, 
sputum conversion rates at 2 months and the determinants of treatment outcomes of 
patients with pulmonary TB and DM. We also planned to assess the effects of glycaemic 
control on the treatment outcomes of sputum positive pulmonary TB.  
Demographics 
In our study, 124 patients were included with 68 diabetics and 58 non-diabetics.  
The baseline demographic characteristics were mostly similar in both the groups except 
for a higher mean age and a male predominance in the DM group.  
Clinical characteristics 
The DM group had a significantly higher percentage of hypertensives. Ethanol 
consumption and smoking was also significantly  higher in the DM group. Symptoms at 
presentation were equal in both the groups. The anthropometric and laboratory 
parameters were significantly different among both the groups. The mean weight and 
BMI were significantly lesser in the NDM group as compared to the DM group. This 
suggests that degree of immunosuppression caused by DM was as severe as the under 
nutrition in the NDM group and was enough to lead to an increased risk of contracting 
TB. Factors causing this level of immunosuppression in patients with DM need to be 
studied.  This co relates with a systematic review of literature which looked at 13 
observational studies and  showed a threefold risk of developing TB in diabetics (12). 
These studies were conducted in Asian countries - Taiwan, Korea, India; the United 
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Kingdom, Russia and the United states of America. The diabetics in our study did not 
have a higher number of patients with past TB as was described in a few studies from 
Egypt, China and the Republic of the Congo which demonstrated higher rates of relapse 
of TB in diabetics (83,84,87). Extrapulmonary TB was more prevalent in the non-
diabetic group (9% in the DM group vs 19% in the NDM group) with a trend towards 
significance (p value – 0.08). This finding was demonstrated in a study conducted in 
Guinea and another study conducted in Mexico (60,69). 
Investigations 
Haemoglobin levels were significantly lower in the non-diabetics when compared with 
the diabetics. The mean albumin levels were lower than normal in both the groups 
(Normal  albumin levels- 3.5- 5.5 in our institution) and the albumin levels were 
significantly lower in the non-diabetics. The mean HbA1c was 9.5 in the DM group and 
5.3 in the NDM group. In the DM group, 9% were newly diagnosed to have DM. Nearly 
70 % of the diabetics were on oral diabetic agents and 18 % were on insulin. The most 
common microvascular complication was diabetic neuropathy which was seen in around 
30% of the patients. Ischaemic heart disease was the most common macrovascular 
complication which was seen in 7% of the patients.  
 The most common X-ray finding in both the groups was consolidation. The presence of  
Fibrocavitatory lesions was similar in both the groups and our study did not demonstrate 
an association between poor glycaemic control and the presence of cavitatory lesions, as 
was demonstrated in a study from Iran (91).  7% of diabetic patients with cavities were 
using insulin. However, there was no significant association between insulin use and the 
presence of cavitatory lesions (p value – 0.49) This finding was in contrast to the finding 
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in a study done in Turkey which showed increased frequency of cavitatory lesions in 
diabetic patients using insulin (62).  
Sputum characteristics of patients 
Sputum smears were negative in 15 % and 26 % in the DM and NDM group 
respectively. These patients had positive sputum Xpert PCR reports. High bacillary load 
(3+ sputum AFB) was seen in 30 % of the non-diabetics as compared with 13% in the 
diabetics, which was statistically significant. These results corroborate  with studies done 
in Indonesia and Turkey which showed lower sputum mycobacterial load in diabetics and 
no co relation between  sputum mycobacterial load and DM respectively(62,71). 
However, Among the 9 patients with a high bacillary load in the DM group, HbA1c 
levels were available for 8 of the patients and all of them had uncontrolled Dm (HbA1c > 
7), which was demonstrated in a study conducted in Korea where uncontrolled diabetics 
had a higher bacillary load as compared with diabetics with optimum diabetic 
control(72). Among these patients, 4 had HbA1c levels > 9 but there was no significant 
association between patients with HbA1c > 9 and high bacillary load (p value – 0.71) as 
was demonstrated in a study from Taiwan (64). 
Drug induced Liver injury 
Though a study done in the United States of America (USA) had shown DM to be an 
independent risk factor for the development of DILI (95), this was not demonstrated in 
our study.  
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Delayed sputum conversion 
11 patients were sputum positive at 2 months of which 6 (15%) were diabetics and 5 
(18%) were non-diabetics. In agreement with other studies conducted in the USA and 
India (17,68,79) our study did not show any relationship between DM and delayed 
sputum conversion. In our study, Smoking was associated with delayed sputum 
conversion in the entire study group [RR - 7.5, 95% CI (2.26 to 25.42), p value- 0.0001] 
and in the DM and NDM subgroup. This finding was in keeping with other studies done 
in Japan, China, the Netherlands and Canada (89–93). COPD was also significantly 
associated with delayed sputum conversion in the entire study group [RR – 6.1, 95% CI 
(2.57 to 14.41), p value- 0.001] and in the DM sub-group, this could be inferred from the 
association between smoking and delayed sputum conversion. The presence of fibro-
cavitatory lesions was significantly associated with delayed sputum conversion in the 
entire population [RR - 3.59, 95% CI (1.29 to 9.97) p value = 0.014] and in the DM sub 
group. This finding was in keeping with a study from China (98). Uncontrolled DM 
(HbA1c > 7)  was not associated with delayed sputum conversion as was demonstrated in 
a few studies (36,82,92). High bacillary load was significantly associated with delayed 
sputum conversion in our study  
[RR – 6.9, 95% CI (2.34 to 20.23), p value = 0.001]. This was demonstrated in the NDM 
group as 100 % of the delayed convertors in the NDM group had a high bacillary load. 
This was in agreement with a few other studies. These studies also demonstrated delayed 
sputum conversion in males. However, this was not shown in our study (104,105).  
Though there was significant association between hypoalbuminemia and delayed sputum 
conversion, we demonstrated a trend towards delayed sputum conversion in this study 
[RR – 3.15, 95% CI (0.736 to 13.484), p value - 0.09].  
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A relationship between delayed sputum conversion and hypoalbuminemia could be 
demonstrated in larger studies.  
There was no statistically significant relationship between having a past history of TB, 
Ethanol consumption, being underweight, anemia and delayed conversion of sputum 
smears which could be demonstrated in our study.  
Effect of Treatment of TB on glycaemic control 
There was a significant impact of TB treatment on glycaemic control as demonstrated by 
a significant reduction in the mean HbA1c before and after treatment of TB in diabetics 
[Mean difference – 1.76, 00195% CI of difference – (1.01 – 2.52) p value – 0.001]. To 
the best of our knowledge, there are very few studies looking at the effect TB treatment 
has on glycaemic control.  A study from China looked at fasting blood glucose levels in 
patients with newly diagnosed DM during initiation of ATT and reported that their blood 
sugar levels were uncontrolled during and after treatment. We could not find any studies 
which look at the glycaemic control after initiation of ATT in patients who are known 
diabetics. Our finding of a decline in HbA1c after ATT treatment has not been reported 
and further studies are needed to look at glycaemic control in known diabetics after ATT 
initiation.   
Mortality 
The mortality rates were 15 % and 7% in the DM and NDM groups respectively. All the 
patients with fatal outcomes had a significant co existing chronic disease or a severe 
infection or a severe metabolic complication like Diabetic Ketoacidosis and 
Hyperglycaemic Hyperosmolar state. A significant association between DM and 
mortality rates could not be demonstrated in our study, which has been demonstrated in 
other studies performed in Tanzania, The USA, India and Taiwan (17,67,69,73,74).  
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There was a significant association between the presence of CKD and IHD contributing 
to mortality in the entire study population and in the DM, NDM sub groups. Anemia was 
also significantly associated with mortality in the entire study group [RR – 6.6, 95% CI 
(0.90 – 49.18), p value - 0.02] 
Patients with fatal outcomes had a lower albumin level [ F-0.425, p value – 0.01, mean 
difference -0.53, 95 % CI of difference (-0.945 to – 0.106)] and higher creatinine levels [ 
F-71.9, p value – 0.001, mean difference 1.29, 95 % CI of difference (0.84 to 1.74)].  
Treatment outcomes  
There was no treatment failure recorded in our study. However, there was a significant 
loss to follow up. Of the initial 68 diabetics and 56 non – diabetics, only 27 and 23 
patients were followed up at 6 months respectively.  At 2 months 41 diabetics and 30 
non-diabetics had followed up. The treatment outcomes were comparable in the DM and 
NDM groups. 57 % in the DM group and 50 % in the NDM group were either cured or 
had completed treatment successfully. Varying effects of DM on TB outcomes have been 
described with some studies conducted in Korea, Saudi Arabia and The USA showing no 
negative effects of DM on TB treatment outcomes or mortality (68,72,79) while a few 
other studies including studies conducted in India, Taiwan, China and Spain which have 
shown increased risk of treatment failure and mortality (78,123–125).  
Multivariate analysis 
Delayed sputum conversion 
Cavitatory lung lesions [p value - 0.05; RR - 6.7, 95% CI - ( 1.01 to 45.61)],  
COPD [p value - 0.006; RR - 60.1, 95% CI - (3.23 to 1116.47)] and a high bacillary load 
[p value - 0.001; RR - 22.5, 95% CI - (3.34 to 151.21)]  were significantly associated 
with delayed sputum conversion.  Smoking was significantly associated with delayed 
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sputum conversion on a univariate analysis. However, Smoking and COPD had almost 
similar relative risks and a 95% CI, hence due to the co linearity of the variables, one of 
them had to be excluded from the multivariate analysis. The relationship between COPD 
and delayed sputum conversion could in effect be secondary to the effect smoking has 
delayed sputum conversion and as a risk factor for developing COPD. This could explain 
the extreme value seen in the upper bound of the 95% class interval. 
Mortality 
On logistic regression, lower albumin levels [p value - 0.02; RR - 3.5, 95% CI - (1.24 to 
9.94)] and CKD [p value - 0.03; RR - 6.1, 95% CI - (1.11 to 33.5)] were associated with 
mortality. 
CONCLUSION  
1. In this study, we demonstrated that Diabetes was not associated with poor 
outcomes or failure of treatment in patients with pulmonary TB.  
2. There was also no association between DM and delayed sputum conversion. 
3. We  could not demonstrate any association between poor glycaemic control and 
delayed sputum conversion or mortality.  
 
LIMITATIONS 
1. There was a significant loss to follow up in this study.  
2. We were unable to achieve the target sample size.  
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